Pfizer reports phase 2b results for monthly obesity drug berobenatide

June 6, 2026 9:00 AM

Pfizer Inc. (NYSE: PFE) presented results from multiple phase 2b studies of berobenatide, an investigational monthly GLP-1 receptor agonist for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found